The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Gene Review

CRCL  -  Creatinine clearance QTL

Homo sapiens

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of CRCL

  • Thrombocytopenia was dose-limiting, its degree was related to dose and CRCL at time of drug administration [1].
  • After entering five patients toxicity appeared to be related to renal function, therefore the individual dose (total dose 20-100 mg m-2 over 5 days) of lobaplatin was modified according to creatinine clearance (CRCL) and escalated in patients [1].
  • METHODS AND RESULTS: We examined the cross-sectional association of PAD, defined as an ankle-brachial index (ABI) <0.9, and renal insufficiency, defined as an estimated creatinine clearance (CRCL) <60 mL. min(-1) [2].
 

Psychiatry related information on CRCL

  • Creatinine clearance (CRCL) was studied in 20 patients on CAPD in relation to the dwell times (DT), in order to establish a personalised dialysis schedule with the best clearance (CL) results, while respecting the patient's life-style [3].
 

High impact information on CRCL

 

Biological context of CRCL

  • MEASUREMENTS AND MAIN RESULTS: Renal function was studied using creatinine clearance (CRCL), determined before, during, and after the operation, and the glomerular filtration rate (GFR) was measured the day before and after the operation by plasma and urine clearance of 51-chromium edetic acid (51Cr-EDTA) [7].
 

Associations of CRCL with chemical compounds

  • Significant decline in CRCL was observed with enalapril treatment just after 1 week of therapy (p = 0.039) and at the end of observation (p = 0.043) [6].
  • The measured urea Kt/V, creatinine clearance (CRCL) and ultrafiltration (UF) were compared with the same data simulated mathematically using the PD ADEQUEST software version 1 [8].
  • In comparison with preoperative determinations, CRCL and GFR values increased significantly after CPB (p < 0.001) and after the operation (p < 0.01) in the patients treated with nifedipine, whereas the two parameters showed a small and not significant reduction at the same times in the control patients [7].
 

Analytical, diagnostic and therapeutic context of CRCL

  • The measured weekly normalized total creatinine clearance (CRCL), weekly total Kt/V, and daily net ultrafiltration (UF) were compared with corresponding mathematically modeled values [9].
  • NKF-DOQI guidelines suggest a Kt/V value of 2.1 and a creatinine clearance (CRCL) value of 63 L/1.73 m2 of body surface area per week as minimum targets in continuous cycling peritoneal dialysis (CCPD) [10].

References

  1. A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days. Gietema, J.A., de Vries, E.G., Sleijfer, D.T., Willemse, P.H., Guchelaar, H.J., Uges, D.R., Aulenbacher, P., Voegeli, R., Mulder, N.H. Br. J. Cancer (1993) [Pubmed]
  2. High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000. O'Hare, A.M., Glidden, D.V., Fox, C.S., Hsu, C.Y. Circulation (2004) [Pubmed]
  3. Peritoneal dialysis prescription: the "Clearance Peak" model. Virga, G., Amici, G., Da Rin, G. The International journal of artificial organs. (1994) [Pubmed]
  4. Genomewide linkage analysis to serum creatinine, GFR, and creatinine clearance in a community-based population: the Framingham Heart Study. Fox, C.S., Yang, Q., Cupples, L.A., Guo, C.Y., Larson, M.G., Leip, E.P., Wilson, P.W., Levy, D. J. Am. Soc. Nephrol. (2004) [Pubmed]
  5. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. Gietema, J.A., Veldhuis, G.J., Guchelaar, H.J., Willemse, P.H., Uges, D.R., Cats, A., Boonstra, H., van der Graaf, W.T., Sleijfer, D.T., de Vries, E.G. Br. J. Cancer (1995) [Pubmed]
  6. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation. Tylicki, L., Rutkowski, P., Renke, M., Rutkowski, B. American journal of nephrology. (2002) [Pubmed]
  7. Effects on renal function of a continuous infusion of nifedipine during cardiopulmonary bypass. Bertolissi, M., Antonucci, F., De Monte, A., Padovani, R., Giordano, F. J. Cardiothorac. Vasc. Anesth. (1996) [Pubmed]
  8. Clinical validation of PD Adequest software: modeling error assessment. Amici, G., Mastrosimone, S., Da Rin, G., Bocci, C., Bonadonna, A. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis. (1998) [Pubmed]
  9. The use of the PD Adequest mathematical model in pediatric patients on chronic peritoneal dialysis. Verrina, E., Amici, G., Perfumo, F., Trivelli, A., Canepa, A., Gusmano, R. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis. (1998) [Pubmed]
  10. Continuous tidal peritoneal dialysis (CTPD) prescription and adequacy targets. Amici, G., Virga, G., Da Rin, G., Bocci, C., Calconi, G. Advances in peritoneal dialysis. Conference on Peritoneal Dialysis. (1998) [Pubmed]
 
WikiGenes - Universities